Natural phytochemicals prevent side effects in BRCA-mutated ovarian cancer and PARP inhibitor treatment
Ovarian cancer is among the most common malignant tumors in gynecology and is characterized by insidious onset, poor differentiation, high malignancy, and a high recurrence rate. Numerous studies have shown that poly ADP-ribose polymerase (PARP) inhibitors can improve progression-free survival (PFS)...
Saved in:
Main Authors: | Chuanlin Wang (Author), Pengning Gao (Author), Jiali Xu (Author), Shanling Liu (Author), Wenda Tian (Author), Jiayu Liu (Author), Lan Zhou (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
by: Tingting Du, et al.
Published: (2022) -
Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018) -
BRCA immunohistochemistry for screening of BRCA mutation in epithelial ovarian cancer patients
by: Tarinee Manchana, et al.
Published: (2020) -
Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation
by: Natalie Shammas, et al.
Published: (2022) -
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
by: Anastasia Navitski, et al.
Published: (2021)